How Can We Help You with Your Projects?

Contact us to discuss the specifics of your project. Our team of experienced scientists is ready to assist you with tailored solutions to meet your unique needs. Whether you need help with assay development, FDA IND, stability study, lot release approval, or other scientific endeavors, we are here to support you.Contact us to learn more about our cell based assay services

How Long Does It Take to Get Started?

We will initiate your project as soon as the proposal is approved and signed by you. Our streamlined process ensures a quick start, minimizing delays and maximizing efficiency. Fill out the form below to email us or click our live chat option to speak with a MarinBio Scientist and get your project underway.

Can You Help with Assay Development and Validation for FDA IND, Lot Release and Stability Study Approval?

Yes, we have over 30 years of expertise in developing and validating cell based assays for FDA IND, lot release or stability study approval. Our team can also liaise directly with the FDA on your behalf, ensuring a smooth and compliant process. Please contact us to learn more about how we can assist you with your assay development and FDA approval needs.

Do You Need a Custom or Tailored Assay?

MarinBio scientists are experienced and creative in designing, developing, validating assays. Some of the assays we perform are listed below, but there are many more that we created, developed and validated. Give us call so that we may help you.

CRISPR Genome Editing In Vivo for the Treatment of Human Genetic Disease

The advent of CRISPR‑Cas systems has revolutionized the gene therapy landscape, enabling targeted genome editing directly within living organisms (in vivo). Unlike ex vivo strategies that modify cells outside the body, vivo gene editing aims to correct pathogenic mutations within target tissues, potentially offering permanent cures after a single treatment.

Introduction

CRISPR-based genome editing has emerged as one of the most transformative biotechnological innovations of the twenty-first century. The discovery that a bacterial adaptive immune system could be repurposed to target and modify specific DNA sequences has opened unprecedented opportunities for treating human disease at its genetic root. Unlike traditional pharmacologic therapies, which often manage symptoms without addressing underlying causes, CRISPR technology enables direct modification of disease-causing genes, offering the potential for curative interventions.

In vivo gene editing refers to the delivery of CRISPR components directly into a patient’s body, where gene modification occurs within the affected tissue itself. This approach differs from ex vivo editing, in which cells are removed from the patient, modified in the laboratory, and then returned. In vivo editing offers the possibility of treating tissues that are difficult or impossible to remove and reinfuse, such as the liver, heart, or central nervous system. It also enables scalable treatment of common diseases such as cardiovascular disorders and protein misfolding diseases, not only rare genetic conditions. The rapid progress of this field over the last several years has moved CRISPR from proof-of-concept studies to advanced human clinical trials and even to the first personalized therapies administered directly to patients.

Mechanism of CRISPR and Its Therapeutic Potential

CRISPR genome editing relies on a programmable system composed primarily of a guide RNA (gRNA) and a CRISPR-associated nuclease such as Cas9 or Cas12. The guide RNA is engineered to match a specific DNA sequence in the human genome. When introduced into a cell, the guide RNA directs the Cas enzyme to the target DNA sequence, where the enzyme binds and introduces a break or modification.

In classical CRISPR editing, Cas9 introduces a double-strand break at the target site. The cell then attempts to repair the break using either non-homologous end joining, which is error-prone and frequently disrupts gene function, or homology-directed repair, which can incorporate a corrective DNA template to restore or alter a gene precisely. More recent tools such as base editors and prime editors modify individual nucleotides or small DNA segments without creating double-strand breaks, improving safety and precision. These mechanisms allow CRISPR to disable harmful genes, correct pathogenic mutations, or modulate gene expression. As a result, CRISPR can potentially treat genetic diseases, metabolic disorders, protein misfolding diseases, and even acquired conditions such as cardiovascular disease by directly altering the genes responsible.

DNA Modifications by CRISPR

CRISPR technology is a versatile genome-editing tool capable of multiple types of DNA modifications. These can be grouped based on the mechanism and the precision of editing.

Gene Knockout (Disruption):

CRISPR can introduce double-strand breaks (DSBs) at a specific DNA sequence.
When the cell repairs these breaks via non-homologous end joining (NHEJ), it often introduces small insertions or deletions (indels) that disrupt the target gene, effectively “knocking it out.”

Gene Knock-in (Insertion/Replacement):

By providing a donor DNA template, CRISPR can guide the cell to repair DSBs through homology-directed repair (HDR).
This allows precise insertion of a new gene, correction of a mutation, or replacement of a DNA segment.

Base Editing (Single-Nucleotide Changes):

Base editors (like cytosine or adenine base editors) can directly convert one base to another (e.g., C→T or A→G) without causing double-strand breaks.
This is highly useful for correcting point mutations in genetic diseases.

Prime Editing (Flexible Precision Editing):

Prime editors combine a modified Cas9 with a reverse transcriptase enzyme to write new DNA sequences at the target site.
They can perform insertions, deletions, or all 12 possible base-to-base conversions more precisely than standard CRISPR or base editors.

Epigenetic Modifications (Gene Regulation without Changing DNA Sequence):

Using a “dead” Cas9 (dCas9) fused to regulatory proteins, CRISPR can activate or repress gene expression.
Examples: dCas9 fused to methyltransferases can add DNA methylation or fused to histone modifiers to change chromatin state.

Chromosomal Rearrangements:

CRISPR can induce larger structural changes, such as inversions, translocations, or deletions of large DNA segments, by targeting multiple sites simultaneously.

In summary, CRISPR can knock out genes, knock in genes, correct single bases, reprogram DNA without cutting, and even rearrange chromosomes. Together, these capabilities make CRISPR not just a gene-editing tool but a comprehensive platform for precise, flexible, and programmable genome engineering, with applications spanning basic research, therapeutic development, and synthetic biology.

In vivo Delivery Technologies

Efficient and safe delivery is the central technical challenge for in vivo gene editing. Lipid nanoparticles are currently the most widely used system. These particles encapsulate CRISPR RNA or protein and fuse with cell membranes, releasing their contents into the cytoplasm. They are non-viral, transient, scalable, and naturally accumulate in the liver, making them ideal for hepatic targets. Adeno-associated virus vectors deliver DNA encoding CRISPR components and provide long-term expression, which is useful for tissues that regenerate slowly, such as the retina or muscle. However, they have limited cargo capacity and can trigger immune responses.

Targeted lipid nanoparticles incorporate surface ligands that bind specific receptors on target cell types, enabling delivery beyond the liver to tissues such as blood stem cells or immune cells. Engineered extracellular delivery vehicles are synthetic or modified viral particles that display ligands for particular cell types and deliver CRISPR protein directly, offering the potential for highly specific cell targeting with reduced immunogenicity.

Table 1. In vivo Delivery Technologies

Delivery Technology	Mechanism of Cell Entry	Advantages	Limitations	Example Use
Lipid nanoparticles (LNPs)	Membrane fusion and endocytosis	Non-viral, transient, scalable, liver-targeted	Limited tissue specificity	Genetic modification of liver
AAV vectors	Receptor binding and endocytosis	Long-term expression, high efficiency	Immune response, cargo size limits	Retinal and muscle therapies
Targeted LNPs	Ligand–receptor binding on target cells	Enables non-liver targeting	Still experimental	Stem cell targeting
Engineered delivery vehicles	Ligand-directed binding and cytoplasmic release	High specificity, reduced immunogenicity	Early development stage	Immune cell targeting

Representative Monogenic Disorders Under Evaluation for In Vivo CRISPR Therapy

The emergence of in vivo CRISPR–Cas gene editing has created the possibility of treating inherited diseases at their genetic source rather than managing their downstream consequences. By enabling targeted, permanent modification of disease-causing genes within affected tissues, this approach represents a conceptual shift from chronic therapy toward potentially curative intervention. The following examples illustrate how in vivo CRISPR strategies are being applied across a range of monogenic disorders, highlighting differences in disease biology, delivery platforms, clinical maturity, and safety considerations.

Hereditary Transthyretin Amyloidosis (ATTR)

Disease etiology.

ATTR is caused by autosomal dominant mutations in the TTR gene, leading to misfolding and deposition of transthyretin protein in peripheral nerves and the heart, resulting in polyneuropathy and cardiomyopathy.

CRISPR approach.

The candidate therapy NTLA‑2001 uses lipid nanoparticle (LNP) delivery of CRISPR‑Cas9 components systemically to the liver, where TTR is predominantly synthesized. The editing strategy employs a guide RNA targeting TTR to induce disruption of protein production, reducing circulating mutant and wild‑type TTR levels.

Clinical status.

Phase I/II studies showed dose‑dependent reductions in serum TTR with manageable safety signals, supporting advancement into later‑stage trials. However, safety events have led to temporary holds and careful monitoring of hepatic toxicity.

Challenges.

As of late 2025, the FDA placed a clinical hold on pivotal trials after a serious safety event involving elevated liver enzymes and bilirubin in a trial participant, prompting a pause in dosing and screening while regulatory review proceeds.

Duchenne Muscular Dystrophy

Disease etiology.

Duchenne Muscular Dystrophy is a severe X‑linked disorder caused by mutations in the DMD gene encoding dystrophin, essential for muscle fiber integrity. Progressive muscle wasting leads to loss of ambulation and premature death.

CRISPR approach.

In vivo strategies seek to restore dystrophin expression by using CRISPR‑Cas9 to excise mutated exons or correct reading frame disruptions. Delivery is commonly via adeno‑associated viruses (AAVs) engineered for muscle tropism.

Preclinical data.

Animal models demonstrate restored dystrophin, improved muscle function, and extended survival following CRISPR editing. Early human studies are in planning or recruiting phases in specialized centers.

Safety considerations.

Immune responses to viral vectors and potential off‑target effects in nonmuscle tissues are ongoing areas of investigation.

Leber Congenital Amaurosis

Disease etiology.

Leber Congenital Amaurosis is an autosomal recessive retinal dystrophy caused by mutations in CEP290, leading to photoreceptor dysfunction and early‑onset blindness.

CRISPR approach.

EDIT‑101 uses AAV to deliver CRISPR machinery directly into the subretinal space to correct the CEP290 intronic mutation. The eye’s immune privileged status and localized anatomy offer distinct advantages for in vivo

Clinical status.

First‑in‑human doses were administered in early trials; while safety profiles were acceptable, clinical efficacy has varied, and development is refining patient selection and dosing.

Hereditary Tyrosinemia Type I

Disease etiology.

Hereditary Tyrosinemia Type I arises from bi‑allelic mutations in the FAH gene, which encodes fumarylacetoacetate hydrolase. Deficiency leads to toxic metabolite accumulation, causing liver and kidney damage.

CRISPR approach.

Preclinical in vivo therapy utilizes CRISPR‑Cas9 delivered via LNPs and viral vectors along with donor templates to correct the point mutation in hepatocytes. Edited cells expand over time, restoring metabolic function.

Preclinical evidence.

Mouse models show efficient genetic repair with functional correction of liver pathology, supporting the feasibility of precise CRISPR‑mediated correction of metabolic disorders.

Together, these genetic disorders demonstrate both the breadth of applicability and the current limitations of in vivo CRISPR therapy. While early clinical and preclinical results show compelling target engagement and therapeutic promise, challenges related to delivery, immune responses, long-term safety, and irreversible genomic alteration remain central to responsible clinical translation. Continued refinement of editing technologies, vector systems, and patient selection will be essential to realizing the full potential of in vivo genome editing as a safe and durable treatment paradigm for inherited disease.

Future Directions and Challenges

The future of in vivo CRISPR therapy holds tremendous promise for transforming the treatment of genetic diseases. Future directions include personalized medicine, expanding therapeutic applications, and improved molecular design. One major direction will be the use of personalized medicine for ultra-rare disorders, where mutation-specific, patient-tailored therapies are becoming feasible due to faster genome sequencing, modular editing platforms, and evolving regulatory pathways that support “N-of-1” treatments. CRISPR applications are also expected to broaden to more common genetic diseases by targeting disease-modifying pathways. Advances in base and prime editing further enhance the safety of in vivo therapies by enabling precise genetic modifications, which reduces genomic damage and makes these approaches particularly suitable for sensitive tissues. Future directions will likely include the integration of artificial intelligence into CRISPR development to improve guide RNA design and predict off-target effects, increasing both efficiency and safety. Collectively, these innovations are poised to expand the reach, precision, and safety of in vivo CRISPR therapies, ushering in a new era of genetic medicine.

Conclusion

CRISPR-based in vivo genome editing represents a fundamental shift in how genetic disease may be treated, moving medicine from chronic symptom management toward durable, potentially curative interventions at the level of DNA. The ability to precisely modify pathogenic genes directly within affected tissues has transformed what were once theoretical possibilities into clinically actionable strategies. Early human trials have already demonstrated the feasibility of safely delivering genome-editing components systemically and achieving therapeutically meaningful gene modification in organs such as the liver, validating in vivo CRISPR as a viable therapeutic modality.

At the same time, significant challenges remain before this technology can be broadly implemented in routine clinical practice. Efficient and tissue-specific delivery, long-term safety, control of off-target effects, immunogenicity of CRISPR components, and ethical and regulatory considerations all require continued investigation and refinement. Advances in delivery platforms, base and prime editing technologies, improved guide RNA design, and computational prediction of editing outcomes are rapidly addressing many of these limitations, suggesting that current barriers are likely to be technical rather than fundamental.

Taken together, the convergence of molecular biology, gene delivery engineering, and clinical translation is positioning in vivo CRISPR editing as a central pillar of future precision medicine. As these technologies mature, they hold the promise not only of transforming the treatment of rare monogenic disorders but also of enabling genetic interventions for common diseases with substantial global health impact. The continued responsible development of in vivo genome editing therefore has the potential to redefine the therapeutic landscape and fundamentally alter the way human disease is understood and treated.

Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.

3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.

3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217.

4. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.